The first family, post-translational modifications, or PTMs, are chemical tags appended to proteins after they are synthesized. Ubiquitin and ubiquitin-like modifiers such as SUMO can be attached to a protein to change its stability, localization, or interaction partners, while phosphorylation, O-GlcNAc glycosylation, and palmitoylation tune enzymatic activity and trafficking with remarkable speed. In the gut, these tags act as precision regulators. They fine-tune the activity of key inflammatory signaling molecules, including the transcription factor NF-κB, the innate immune receptors NOD2 and NLRP3, and components of the TNF-α and interleukin-17 pathways. The review catalogs an extensive cast of E3 ubiquitin ligases, such as TRIM8, TRIM25, RNF186, and PELI3, alongside deubiquitinases like CYLD, USP7, and USP25, that add or remove ubiquitin marks on these targets and thereby amplify or dampen inflammatory signals.

The second family operates one step upstream, on the RNA itself. RNA modifications, including N6-methyladenosine, the most abundant internal mark on messenger RNA, N4-acetylcytidine, and adenosine-to-inosine RNA editing, are installed, read, and erased by dedicated enzymes. The methyltransferase complex of METTL3 and METTL14 writes m6A marks, proteins such as YTHDF2 and IGF2BP2 read them, and the demethylase ALKBH5 erases them. The deaminase ADAR1 converts adenosine to inosine in double-stranded RNA, altering both coding potential and immune recognition of RNA transcripts. These modifications act as rapid response regulators: they change how efficiently specific messenger RNAs are translated into proteins, how long those transcripts persist, and how the innate immune system interprets them, all without altering the underlying genome.

The central claim of the review is that these two layers talk to each other extensively, and that this crosstalk is what allows the intestinal epithelium to respond quickly and precisely to injury. The authors describe a synthesis-precision regulation cascade: RNA modifications rapidly adjust the production of effector proteins, while PTMs then fine-tune the activity, stability, and localization of the proteins that have just been made. This two-step logic ensures that barrier repair and inflammation resolution happen efficiently, because the cell can both control how much of a protein is produced and modulate what that protein does once it exists. Neither layer alone achieves this level of control.

Concrete molecular examples illustrate the principle. In innate immune signaling, ubiquitination of RIP2, the kinase downstream of the Crohn’s disease risk gene NOD2, controls NF-κB activation, while RNA editing and m6A modification shape the expression of inflammatory transcripts in macrophages and epithelial cells. In the hypoxic environment of an inflamed gut, the stability of HIF-1α, a master regulator of barrier protection, is governed by PTM-dependent degradation pathways, and its downstream transcriptional output is further shaped by RNA modification machinery. Autophagy regulators such as ATG5 and AMBRA1, central to the cell’s ability to handle intracellular bacteria, are likewise controlled at both the transcript level through m6A-dependent processing and the protein level through ubiquitin-like conjugation systems.

Critically, the review emphasizes that PTMs and RNA modifications can act either synergistically or antagonistically on shared signaling pathways. When both layers push in the same direction, for example when m6A-driven translation of a pro-inflammatory cytokine coincides with ubiquitin-mediated stabilization of the transcription factors that induce it, inflammation escalates sharply. When the layers oppose each other, the outcome can be restraint or resolution. The dynamic balance between these opposing inputs, rather than the absolute level of any single modification, appears to determine the cellular outcome. This reframes IBD pathogenesis as a systems-level failure of regulatory coordination rather than a simple excess of any one inflammatory pathway.

Another key theme is specificity. The crosstalk between the two modification layers is pronouncedly cell-type dependent and disease-stage dependent. Epithelial cells, dendritic cells, macrophages, innate lymphoid cells, T helper 1 and T helper 17 subsets, and intestinal stem cells each deploy distinct combinations of writers, erasers, readers, ligases, and deubiquitinases. The same modification network that drives epithelial barrier breakdown in active disease may support stem cell-driven repair during remission. The authors argue that this cell-type and stage specificity contributes significantly to the clinical heterogeneity of IBD, helping to explain why patients with seemingly similar diagnoses follow such different courses and respond so differently to therapy.

The therapeutic implications are substantial. Existing IBD drugs, including TNF-α blockers, interleukin-12 and interleukin-23 pathway inhibitors, and 5-aminosalicylic acid, target inflammatory cytokines and their receptors. The modification network offers a deeper layer of intervention. Enzymes that write, erase, or read RNA modifications, such as METTL3, ALKBH5, and ADAR1, are increasingly druggable, as are E3 ubiquitin ligases and deubiquitinases that control signaling protein stability. Small molecules targeting the ubiquitin-proteasome system and m6A machinery are already in development in oncology, and the review suggests that repurposing and refining these approaches for intestinal inflammation is a realistic near-term goal. Modulating the crosstalk itself, rather than a single node, could in principle restore the regulatory balance that chronic disease has disrupted.

Diagnostic potential follows a parallel logic. Because modification patterns are cell-type specific and stage dependent, the authors propose that signatures of RNA modifications and PTM-associated enzymes could serve as biomarkers that distinguish active inflammation from remission, predict flares, or stratify patients for targeted therapy. Such biomarkers could be measured in intestinal biopsies or potentially in circulating immune cells and extracellular RNA, offering a more dynamic readout of disease state than static genetic risk scores. The review frames this as an emerging frontier, noting that systematic mapping of the modification landscape in defined IBD patient cohorts remains an early-stage but rapidly advancing endeavor.

The work, funded by the National Natural Science Foundation of China and regional research programs in Jiangsu and Wuxi, arrives as single-cell transcriptomics and modification-mapping technologies make it feasible to profile these chemical tags at unprecedented resolution. Its broader message is one of convergence: epigenetics, post-transcriptional regulation, and protein homeostasis, long studied in separate silos, are best understood as one layered control system. For a disease as heterogeneous and stubborn as inflammatory bowel disease, that integrated view may be exactly what is needed to turn molecular detail into clinical benefit, from new drug targets to biomarkers that tell clinicians which patients need which intervention, and when.

Subject of Research: Crosstalk between post-translational protein modifications and RNA modifications in the pathogenesis of inflammatory bowel disease

Article Title: Crosstalk between post-translational and RNA modifications in inflammatory bowel disease: a comprehensive review

Article References: Zhou, J., Fang, B., Zhang, Y., Liu, Y., & Wang, F. (2026). Crosstalk between post-translational and RNA modifications in inflammatory bowel disease: a comprehensive review. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-09006-z

Image Credits: AI Generated

DOI: 10.1186/s12967-026-09006-z

Keywords: inflammatory bowel disease, post-translational modifications, RNA modifications, m6A methylation, ubiquitination, RNA editing, NF-κB, intestinal barrier, Crohn's disease, ulcerative colitis, therapeutic targets, biomarkers